Epitopes of microbial and human heat shock protein 60 and their recognition in myalgic encephalomyelitis.
Elfaitouri, Amal, Herrmann, Björn, Bölin-Wiener, Agnes et al. · PloS one · 2013 · DOI
Quick Summary
This study looked at whether ME/CFS patients have different immune responses to heat shock protein 60 (HSP60), a protein found in both human cells and bacteria. Researchers tested blood samples from ME/CFS patients and healthy people, finding that some ME/CFS patients had specific antibodies against a bacterial version of this protein. This suggests that a past infection might trigger the immune system to attack proteins in the body, which could contribute to ME/CFS.
Why It Matters
This work provides biological evidence supporting the hypothesis that ME/CFS may be triggered by infection-induced autoimmunity, a mechanism that could explain why many patients report symptom onset following infections. Identifying specific immune markers could eventually help develop diagnostic tests and guide treatment strategies for ME/CFS patients.
Observed Findings
IgM antibodies to Chlamydia pneumoniae HSP60 were detected in 24% (15/61) of ME patients versus 0.25% (1/399) of non-ME controls at high cutoff (p<0.0001)
HSP60 peptides, particularly from helix I region, showed both chaperonin-like activity and antibody binding capacity, suggesting potential functional interference
Cross-reactive epitopes between human and microbial HSP60 were identified in ME patient samples
Anti-HSP60 responses were predominantly found in a subset rather than across all ME patients studied
Inferred Conclusions
Infection-induced autoimmunity involving HSP60 molecular mimicry may contribute to ME/CFS pathogenesis in susceptible individuals
A 25-antigen HSP60 panel, particularly the Chlamydia pneumoniae peptide, may serve as a potential biomarker for a subset of ME/CFS patients
The immune response to HSP60 may represent a bridge between infectious trigger and chronic autoimmune dysfunction in ME/CFS
Remaining Questions
Is the presence of anti-HSP60 IgM antibodies actually causal in ME/CFS pathogenesis, or merely a marker of past infection?
Do these antibodies persist long-term or fluctuate, and does their presence correlate with symptom severity or progression?
What This Study Does Not Prove
This study does not prove that HSP60 antibodies cause ME/CFS—the cross-sectional design cannot establish causation, only association. It also does not demonstrate that all ME/CFS patients have this immune abnormality, since the antibodies were found in only a subset of patients. Finally, it does not clarify whether these antibodies persist or fluctuate over time, or whether they directly contribute to illness severity.